R
Rona Yaeger
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 193
Citations - 17628
Rona Yaeger is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 41, co-authored 138 publications receiving 10636 citations. Previous affiliations of Rona Yaeger include Philips & Columbia University Medical Center.
Papers
More filters
Journal ArticleDOI
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M. Samstein,Chung-Han Lee,Chung-Han Lee,Alexander N. Shoushtari,Alexander N. Shoushtari,Matthew D. Hellmann,Matthew D. Hellmann,Ronglai Shen,Yelena Y. Janjigian,Yelena Y. Janjigian,David Barron,Ahmet Zehir,Emmet Jordan,Antonio Omuro,Thomas Kaley,Sviatoslav M. Kendall,Robert J. Motzer,Robert J. Motzer,A. Ari Hakimi,Martin H. Voss,Martin H. Voss,Paul Russo,Jonathan E. Rosenberg,Jonathan E. Rosenberg,Gopa Iyer,Gopa Iyer,Bernard H. Bochner,Dean F. Bajorin,Dean F. Bajorin,Hikmat Al-Ahmadie,Jamie E. Chaft,Jamie E. Chaft,Charles M. Rudin,Charles M. Rudin,Gregory J. Riely,Gregory J. Riely,Shrujal S. Baxi,Shrujal S. Baxi,Alan L. Ho,Alan L. Ho,Richard J. Wong,David G. Pfister,David G. Pfister,Jedd D. Wolchok,Jedd D. Wolchok,Christopher A. Barker,Philip H. Gutin,Cameron Brennan,Viviane Tabar,Ingo K. Mellinghoff,Lisa M. DeAngelis,Charlotte E. Ariyan,Nancy Y. Lee,William D. Tap,William D. Tap,Mrinal M. Gounder,Mrinal M. Gounder,Sandra P. D'Angelo,Sandra P. D'Angelo,Leonard B. Saltz,Leonard B. Saltz,Zsofia K. Stadler,Zsofia K. Stadler,Howard I. Scher,Howard I. Scher,José Baselga,José Baselga,Pedram Razavi,Pedram Razavi,Christopher A. Klebanoff,Christopher A. Klebanoff,Rona Yaeger,Rona Yaeger,Neil H. Segal,Neil H. Segal,Geoffrey Y. Ku,Geoffrey Y. Ku,Ronald P. DeMatteo,Marc Ladanyi,Naiyer A. Rizvi,Michael F. Berger,Nadeem Riaz,David B. Solit,Timothy A. Chan,Luc G. T. Morris +84 more
TL;DR: Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.
Journal ArticleDOI
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir,Ryma Benayed,Ronak Shah,Aijazuddin Syed,Sumit Middha,Hyunjae R. Kim,Preethi Srinivasan,Jianjiong Gao,Debyani Chakravarty,Sean M. Devlin,Matthew D. Hellmann,David Barron,Alison M. Schram,Meera Hameed,Snjezana Dogan,Dara S. Ross,Jaclyn F. Hechtman,Deborah DeLair,Jinjuan Yao,Diana Mandelker,Donavan T. Cheng,Raghu Chandramohan,Abhinita Mohanty,Ryan Ptashkin,Gowtham Jayakumaran,Meera Prasad,Mustafa H Syed,Anoop Balakrishnan Rema,Zhen Y Liu,Khedoudja Nafa,Laetitia Borsu,Justyna Sadowska,Jacklyn Casanova,Ruben Bacares,Iwona Kiecka,Anna Razumova,Julie B Son,Lisa Stewart,Tessara Baldi,Kerry Mullaney,Hikmat Al-Ahmadie,Efsevia Vakiani,Adam Abeshouse,Alexander V Penson,Philip Jonsson,Niedzica Camacho,Matthew T. Chang,Helen Won,Benjamin Gross,Ritika Kundra,Zachary J. Heins,Hsiao-Wei Chen,Sarah Phillips,Hongxin Zhang,Jiaojiao Wang,Angelica Ochoa,Jonathan Wills,Michael H. Eubank,Stacy B. Thomas,Stuart Gardos,Dalicia N. Reales,Jesse Galle,Robert Durany,Roy Cambria,Wassim Abida,Andrea Cercek,Darren R. Feldman,Mrinal M. Gounder,A. Ari Hakimi,James J. Harding,Gopa Iyer,Yelena Y. Janjigian,Emmet Jordan,Ciara Marie Kelly,Maeve A. Lowery,Luc G. T. Morris,Antonio Omuro,Nitya Raj,Pedram Razavi,Alexander N. Shoushtari,Neerav Shukla,Tara Soumerai,Anna M. Varghese,Rona Yaeger,Jonathan A. Coleman,Bernard H. Bochner,Gregory J. Riely,Leonard B. Saltz,Howard I. Scher,Paul Sabbatini,Mark E. Robson,David S. Klimstra,Barry S. Taylor,José Baselga,Nikolaus Schultz,David M. Hyman,Maria E. Arcila,David B. Solit,Marc Ladanyi,Michael F. Berger +99 more
TL;DR: A large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer are compiled and identified clinically relevant somatic mutations, novel noncoding alterations, and mutational signatures that were shared by common and rare tumor types.
Journal ArticleDOI
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale,Rona Yaeger,Sebastijan Hobor,Elisa Scala,Manickam Janakiraman,David Liska,Emanuele Valtorta,Roberta Schiavo,Michela Buscarino,Giulia Siravegna,Katia Bencardino,Andrea Cercek,Chin Tung Chen,Silvio Veronese,Carlo Zanon,Andrea Sartore-Bianchi,Marcello Gambacorta,Margherita Gallicchio,Efsevia Vakiani,Valentina Boscaro,Enzo Medico,Martin R. Weiser,Salvatore Siena,Federica Di Nicolantonio,David B. Solit,Alberto Bardelli +25 more
TL;DR: KRAS mutations are identified as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.
Journal ArticleDOI
OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty,Jianjiong Gao,Sarah Fierberg Phillips,Ritika Kundra,Hongxin Zhang,Jiaojiao Wang,Julia E. Rudolph,Rona Yaeger,Tara Soumerai,Moriah H. Nissan,Matthew T. Chang,Sarat Chandarlapaty,Tiffany A. Traina,Paul K. Paik,Alan L. Ho,Feras M. Hantash,Andrew Grupe,Shrujal S. Baxi,Margaret K. Callahan,Alexandra Snyder,Ping Chi,Daniel C. Danila,Mrinal Gounder,James J. Harding,Matthew D. Hellmann,Gopa Iyer,Yelena Y. Janjigian,Thomas Kaley,Douglas A. Levine,Maeve A. Lowery,Antonio M. P. Omuro,Michael A. Postow,Dana Rathkopf,Alexander N. Shoushtari,Neerav Shukla,Martin H. Voss,Ederlinda Paraiso,Ahmet Zehir,Michael F. Berger,Barry S. Taylor,Leonard B. Saltz,Gregory J. Riely,Marc Ladanyi,David M. Hyman,José Baselga,Paul Sabbatini,David B. Solit,Nikolaus Schultz +47 more
TL;DR: OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions.
Journal ArticleDOI
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Scott Kopetz,Axel Grothey,Rona Yaeger,Eric Van Cutsem,Jayesh Desai,Takayuki Yoshino,Harpreet Wasan,Fortunato Ciardiello,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod Kyrre Guren,Hendrik Tobias Arkenau,Pilar García-Alfonso,Per Pfeiffer,Sergey Orlov,Sara Lonardi,Elena Elez,Tae Won Kim,Jan H.M. Schellens,Christina Guo,Asha Krishnan,Jeroen Dekervel,Van Morris,Aitana Calvo Ferrándiz,Line Schmidt Tarpgaard,Michael Braun,Ashwin Gollerkeri,Christopher Hunt Keir,Kati Maharry,Michael D Pickard,Janna Christy-Bittel,Lisa Anderson,Victor Sandor,Josep Tabernero +34 more
TL;DR: A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF V600E mutation.